The press release contains no hard financial data or guidance. The clinical and real-world data are positive for brand perception but do not constitute a near-term catalyst. Monitor for future FDA registration updates on the filler program or quarterly earnings for revenue contribution from these products.
Price Chart
Executive Summary
Obagi Medical, a Waldencast subsidiary, presented interim clinical and real-world data at the Music City SCALE meeting for its NU-GEN Cellular Renewal Serum and Saypha MagIQ hyaluronic acid filler. The data shows strong practitioner adoption (94% believe MagIQ complements their current fillers) and clinical efficacy (NU-GEN clinically proven to reduce perceived skin age by up to six years). While the data is positive for the brand's pipeline, it is early-stage (interim, non-pivotal) and does not represent a near-term revenue catalyst for Waldencast.
Key Facts
- Interim data from ALOHA program: 94% of injectors believe Obagi Saypha MagIQ complements their current filler options.
- NU-GEN Cellular Renewal Serum clinically proven to reduce perceived skin age by up to six years in a 12-week study.
- 43% of patients evaluating MagIQ also evaluating Obagi skincare, indicating cross-selling potential.
- Data presented at Music City SCALE meeting (May 13-17, 2026), a medical conference, not a regulatory milestone.
- Obagi Medical is the fastest-growing professional skincare brand in the U.S. in 2024, per the press release.
Financial Impact
No financial figures disclosed. Data is early-stage and non-binding; no revenue or earnings impact quantified.
Risk Factors
- Data is interim and non-pivotal; full results may differ.
- No FDA approval or regulatory milestone achieved, filler program still in registration phase.
- Waldencast is a small-cap ($209M) with limited liquidity; stock may not react to early-stage data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $0.7500 | awaiting T+5 | awaiting T+5 | No price |
Oct 15, 2026 12d ago | 6-K | $0.7500 | awaiting T+5 | awaiting T+5 | No price |
Oct 15, 2026 12d ago | 15-12G | $0.7500 | awaiting T+5 | awaiting T+5 | No price |
Oct 14, 2026 14d ago | EFFECT | $0.8100 | awaiting T+5 | awaiting T+5 | No price |
Oct 14, 2026 14d ago | EFFECT | $0.8100 | awaiting T+5 | awaiting T+5 | No price |
Oct 14, 2026 14d ago | EFFECT | $0.8100 | awaiting T+5 | awaiting T+5 | No price |
Sep 28, 2026 29d ago | Press Release | $0.9277 $0.8794 | ▲ +5.21% | ▲ +7.15% | No price |
Sep 24, 2026 4w ago | 6-K | $1.03 $0.8794 | ▲ +14.62% | ▲ +14.40% | No price |
Sep 24, 2026 4w ago | Press Release | $1.03 $0.8794 | ▲ +14.62% | ▲ +14.40% | No price |
Sep 14, 2026 6w ago | Press Release | $1.18 $1.10 | ▲ +6.78% | ▲ +6.89% | No price |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers